We published our semiannual report 2023 on August 26, 2023. In the 1st half of the year, we realized RMB 199 million in revenue
On June 9, 2023, the Synthetic Biology Technology Development Summit was held in Wuhan Optics Valley. The Summit was hosted by China Biotech Fermentation Industry Association and jointly undertaken by CABIO Biotech (Wuhan) Co., Ltd., Hubei Society for Mic
On April 26, Jinhaikang obtained a baby liquid FSDU manufacturing license — also the first in Guangdong. The event marked the enablement by Cabio, a biotechnological giant, of its advantage in nutrition and healthcare in cooperation with Jinhaikang
CABIO showcases three new ingredients — HMOs, Salecan® β-glucan and elastin — as well as its already well-known ARA, algal oil DHA, β-Carotene and sialic acid (SA) during the exhibition.
CABIO, a provider of high-quality functional ingredients and innovative solutions for customers worldwide, has been participating in the event for many years, with the aim of sharing its research results and innovative solutions with consumers and industr
Official Ground-breaking Ceremony of Wuhan Synthetic Biology Innovation Center & CABIO R&D Center Investment Project.
On September 7-9, 2022, The CABIO International team participated in the Food Ingredients Asia in Indonesia.
In 2021, CABIO reaped RMB351,109,348.43, up by 8.55% from the preceding year. The net profit attributable to equity holders of the Company totaled RMB128,578,881.86, down by 1.54% from the preceding year.
CABIO has obtained USDA Organic certification for its Docosahexaenoic Acid Oil, Aquatic plants Seaweed and DHA Algae Oil.